白雲山(00874.HK):廣州醫藥擬增資擴股引入戰略合作伙伴及對管理層及核心骨幹員工持股
格隆匯8月6日丨白雲山(00874.HK)宣佈,為滿足公司控股子公司廣州醫藥股份有限公司進一步做大做強業務規模、興建醫藥物流設施、延伸醫藥供應鏈等需要,進一步提高醫藥公司的市場滲透能力,醫藥公司擬通過增資擴股引入戰略合作伙伴及對管理層及核心骨幹員工持股。增資完成後,醫藥公司的總股本將由222,700萬股增加至不多於260,946.99萬股。
本次增資擴股擬通過增量發行新股方式引入普通投資者、戰略投資者,同時引入管理層及核心骨幹員工持股,使醫藥公司變為由原股東白雲山、ALLIANCEBMP LIMITED與投資方共同持股的股份有限公司。醫藥公司擬向普通投資者增發不多於14,342.62萬股股份,增資金額不高於人民幣3.6億元;向戰略投資者增發不多於19,920.31萬股股份,增資金額不高於人民幣5億元;向管理層及核心骨幹員工持股平台增發不多於3,984.06萬股股份,增資金額不高於人民幣1億元,最終增發股份數量根據廣州產權交易所公開徵集的投資方實際增資的情況並經醫藥公司董事會及股東大會審議後確定。
廣州醫藥有限公司成立於1951年,系公司與聯合美華有限公司(ALLIANCEBMP LIMITED)合資的公司,主要從事醫藥批發和零售業務,公司持有其80%的股權。
目前醫藥公司已完成股份制改造,財務水平穩健,具備進一步增資擴股的良好基礎。通過本次增資擴股有利於優化醫藥公司股東結構,提高治理水平;引入戰略投資者以增強醫藥公司長期的核心競爭力和盈利能力,有利於醫藥公司的長遠發展;有利於發揮員工積極性,加速實現醫藥公司發展戰略。增資完成後,醫藥公司仍為本公司控股子公司,不會對本公司現有業務產生不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.